FLGT

$15.43

Market ClosedAs of Mar 17, 8:00 PM UTC

Fulgent Genetics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$15.43
Potential Upside
5%
Whystock Fair Value$16.20
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic t...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$481.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-5.51%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.03

Recent News

Simply Wall St.
Mar 2, 2026

Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused Expansion - What's Changed

Fulgent Genetics reported its 2025 results in the past, with revenue rising to US$322.67 million while the net loss widened to US$60.51 million, and it issued 2026 guidance calling for about US$350.00 million in revenue alongside ongoing investment in oncology and AI-enabled lab services. The company also closed acquisitions of Bako Diagnostics and StrataDx and advanced its cancer drug candidates and digital pathology platform, potentially reducing customer concentration risk and broadening...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 1, 2026

A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance

Fulgent Genetics (FLGT) has sparked fresh attention after releasing full year 2025 results, reporting revenue of US$322.67 million and a net loss of US$60.51 million, along with 2026 revenue guidance of about US$350 million. See our latest analysis for Fulgent Genetics. The earnings release and 2026 revenue guidance have arrived alongside heavy selling pressure, with the 1 day share price return of 38.09% decline and year to date share price return of 40.09% decline, while the 5 year total...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 27, 2026

Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges

Fulgent Genetics Inc (FLGT) reports a 14% annual revenue increase, strategic acquisitions, and new market opportunities despite facing significant customer revenue loss.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Feb 27, 2026

Top Midday Decliners

Fulgent Genetics (FLGT) reported Friday Q4 sales below market expectations, and its forecasts for no

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 27, 2026

Fulgent Genetics Q4 Earnings Call Highlights

Fulgent Genetics (NASDAQ:FLGT) used its fourth-quarter and full-year 2025 earnings call to outline continued growth in its laboratory services business, accelerating investments in digital pathology and AI, and progress across its therapeutic development pipeline. Management also addressed a near-te

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.